Abstract

Aims

The effects of statin therapy in patients with chronic kidney disease (CKD) remain uncertain. We undertook a systematic review and meta-analysis to investigate the effects of statin on major clinical outcomes.

Methods and results

We systematically searched MEDLINE, Embase, and the Cochrane Library for trials published between 1970 and November 2011. We included prospective, randomized, controlled trials assessing the effects of statins on cardiovascular outcomes in people with kidney disease. Summary estimates of relative risk (RR) reductions were calculated with a random effects model. Thirty-one trials that include at least one event were identified, providing data for 48 429 patients with CKD, including 6690 major cardiovascular events and 6653 deaths. Statin therapy produced a 23% RR reduction (16–30) for major cardiovascular events (P<0.001), an 18% RR reduction (8–27) for coronary events, and 9% (1–16) reduction in cardiovascular or all-cause deaths, but had no significantly effect on stroke (21%, –12 to 44) or no clear effect on kidney failure events (5%, −1 to 10). Adverse events were not significantly increased by statins, including hepatic (RR 1.13, 95% CI 0.92–1.39) or muscular disorders (RR 1.02, 95% CI 0.95–1.09). Subgroup analysis demonstrated the relative effects of statin therapy in CKD were significantly reduced in people with advanced CKD (P < 0.001) but that the absolute risk reductions were comparable.

Conclusion

Statin therapy reduces the risk of major cardiovascular events in patients with chronic kidney disease including those receiving dialysis.

See page 1772 for the editorial comment on this article (doi:10.1093/eurheartj/eht136)

Introduction

Chronic kidney disease (CKD) is a major public health problem.1 Cardiovascular disease (CVD) continues to be the leading cause of morbidity and mortality among people with CKD worldwide, with rates of cardiovascular events and mortality consistently increasing as kidney function declines.2,3 Dialysis patients have mortality rates up to 40-fold higher than the general population, with CVD being responsible for up to 50% of these deaths.4 Patients with CKD have higher prevalence of a number of risk factors for CVD, including lipid abnormalities, hypertension, obesity, and diabetes.

Kidney Disease Outcome Quality Initiative (K/DOQI) clinical practice guidelines have recommended statin therapy for the prevention of CVD in patients with CKD and high-LDL cholesterol (LDL-C) levels.5 However, the value of this approach continues to be debated, particularly in those with the most advanced kidney dysfunction. Levels of cholesterol in patients with kidney disease do not always have the same log-linear relationship with cardiovascular events observed in the general population.6 Indeed, a ‘U’-shaped or inverse relationship has been described in cohort studies of dialysis patients where people with the lowest levels of LDL-C have the worst outcomes. The burden of CVD may not be predominantly due to atherosclerotic disease in people with severely decreased GFR when compared with people with normal renal function. Emerging data suggest the pattern of cardiovascular pathology may be different in advanced CKD, with vascular stiffness and calcification, structural heart disease, and sympathetic overactivity contributing to an increasing risk of cardiac arrhythmia and heart failure.7 Thus, the effect of statin therapy may be less compared with the general population. In the past few years, several large-scale trials of statin therapy in people with CKD have been completed, including the recent large SHARP (Study of Heart and Renal Protection) trial.8 Although some of these trials have shown benefit,8 others have shown no effect,9,10 leading to uncertainty about the presence and magnitude of cardiovascular protective effects and therefore difficulties for clinicians in the interpretation of the results.

Two recent overviews have investigated the effect of statin in patients with CKD. However, both have not evaluated the effect of kidney function on the statin therapy.11,12 In this systematic review, we sought to synthesize all the available clinical trial data and define better the balance of risks and benefits of statin in patients with CKD and also the effect of kidney function on statin use.

Methods

Data sources, search strategy, and selection criteria

We performed a systematic review of the published literature according to the approach recommended by the statement for the conduct of meta-analyses of intervention studies. We included data from randomized, controlled trials in which statin was given for at least 6 months to patients with CKD. These data were extracted either from studies conducted solely in people with kidney disease, or from subsets of other trials where data on the CKD population could be obtained.

Relevant studies were identified by searching the following data sources: MEDLINE via Ovid (from 1950 to November 2011), Embase (from 1966 to November 2011), and the Cochrane Library database (Cochrane Central Register of Controlled Trials; no date restriction), with relevant text words and medical subject headings that included all spellings of ‘kidney disease’, ‘dyslipidemia’, ‘hypercholesterolemia’, ‘cardiovascular disease’, ‘myocardial infarction’, ‘revascularisation’, ‘stroke’, ‘simvastatin’, ‘atorvastatin’, ‘rosuvastatin’, ‘pravasatin’ (see Supplementary material online). Trials were considered without language restriction. Reference lists from identified trials and review articles were manually scanned to identify any other relevant studies. The ClinicalTrials.gov website was also searched for randomized trials that were registered as completed but not yet published.

The literature search, data extraction, and quality assessment were undertaken independently by two authors (W.H. and L.Y.) using a standardized approach. All completed randomized, controlled trials assessing the effects of statin compared with placebo and/or compared with conventional therapy in CKD, and that reported one or more of the primary or secondary outcomes, were eligible for inclusion. Trials that recruited patients with kidney transplants were not included in this study.

Data extraction, quality assessment, and outcome estimation

Published reports were obtained for each eligible trial, and relevant information was extracted into a spreadsheet. The data sought included baseline patient characteristics (age, sex, history of diabetes, history of CVD, mean systolic and diastolic blood pressure values, lipid concentrations), statin used, dose of drug, follow-up duration, change in LDL-C concentrations, outcome events, and adverse events. Study quality was judged by the proper conduct of randomization, concealment of treatment allocation, similarity of treatment groups at baseline, the provision of a description of the eligibility criteria, completeness of follow-up, and the use of an intention-to-treat analysis, and was quantified with the Jadad scale.13 Any disagreement in the abstracted data was adjudicated by a third reviewer (J.L.).

We collected data for major cardiovascular events (defined as a composite including fatal or non-fatal myocardial infarction, fatal or non-fatal stroke, revascularization procedures, cardiovascular death, and heart failure, or comparable definitions used by individual authors), cardiovascular mortality, all-cause death, new onset cancer, and other drug-related adverse events. We listed all cardiovascular events for each included studies in Supplementary material online, Table S2. Trials that compare high- vs. low-dose statin therapy met the inclusion criteria but in a separate analysis. Kidney failure events were defined as a 25% decrease in the estimated GFR, doubling of serum creatinine, or end stage renal disease (ESRD) as defined by the authors of each study.

When required quantitative data were not provided in the relevant article from the text, we use the g3 data software (http://www.frantz.fi/software/g3data.php) to extract exact numbers from published figures.

Statistical analysis

Individual patient data were not available from the studies in this analysis, so tabular data were used. Individual study relative risks (RRs) and 95% CIs were calculated from event numbers and total population at risk extracted from each trial, using a standard method14 before data pooling. In the calculation of risk ratios, the total number of patients randomly assigned in each group was used as the denominator. Summary estimates of risk ratios were obtained with a random effects model. The percentage of variability across studies attributable to heterogeneity beyond chance was estimated with the I² statistic. For each trial, we calculated not only the average risk reduction, but also the average risk reduction per 1.0 mmol/L LDL-C reduction at the end of each trial where data were available (1 divided by the observed LDL reduction, for example, if the RR was 0.7 and the reduction in systolic blood pressure was 0.8 mmol/L, the standardized RR estimate was 0.71/0.8.15

Potential publication bias was assessed with the Egger test and represented graphically with Begg funnel plots of the natural log of the RR vs. its standard error.

We explored potential heterogeneity in the estimates of treatment effect with univariate meta-regression (for end-of-trial parameters such as achieved LDL-C concentrations) and by comparing summary results obtained from the subsets of studies grouped by number of patients, number of mortality events, publication year, statin used, diabetic status, stage of CKD, baseline morbidity, and study quality. A two-sided P-value <0.05 was regarded as significant for all analyses. All statistical analyses were done with STATA (version 12.0).

Results

The literature search yielded 2310 articles, of which 134 were reviewed in full text (Figure 1). Of these, 31 randomized, controlled trials met the inclusion criteria. These trials included a total of 48 429 patients with CKD, in whom 6690 major cardiovascular events were reported from 22 studies, and 6653 deaths from 23 studies. Study follow-up duration ranged from 6 months to 4.9 years. Thirteen trials were placebo-controlled and 18 trials used open-label designs. Ten trials reported post hoc analyses of the subgroup with CKD, four compared intensive lipid-lowering therapy to conventional or low-dose therapy. Formal statistical testing suggested the possibility of publication bias for the outcome of major cardiovascular outcomes with a borderline Egger test result (P = 0.062, see Supplementary material online, Figure S1).

Figure 1

Identification process for eligible studies.

Figure 1

Identification process for eligible studies.

Table 1 summarizes the characteristics of the included studies. Ten trials with 4503 participants were exclusively undertaken in dialysis patients,9,10,16–18 18 trials (n = 33 252) were in non-dialysis patients, and another 3 trials (n = 10 029) had a mixed population that included both dialysis and non-dialysis patients. Baseline estimated GFR levels for the participants in the trials were reported in the published paper or could be calculated or estimated from the inclusion criteria (Figure 2). Two trials were undertaken in people with diabetes and CKD.

Table 1

Characteristics of studies reporting the effects of statin in patients with chronic kidney disease

Study Year Inclusion criteria Definition of CKD Duration of time, year Treatment group Control group Mean age, years Baseline
 
Number of patients History of CVD (%) 
LDL- C, mmol/L eGFR, mL/min/1.73 m2 
Han, 2011 2011 PD > 3 months Dialysis 0.5 Rosuvastatin 10 mg/day + ARB 80 mg/day Placebo + ARB 80 mg/day 49 4.83 NA 124 
ATTEMP 2011 CKD stage 3 patients with metabolic syndrome, no CVD or DM CKD stage 3, eGFR = 30–59 mL/min/1.73 m2 3.5 Atorvastatin LDL-C target on 100 mg/L Atorvastatin LDL-C target on 130 mg/dL 57 4.37 47.60 349 
SHARP 2011 History of CKD, age > 40, Scr: men >150 µmol/L, women >130 µmol/L Increased Scr: men >150 µmol/L, women >130 µmol/L Simvastatin + ezetimibe Placebo 62 2.70 26.60 9438 15 
Air Force/Texas 2009 Hyperlipidaemia, no CVD or DM eGFR < 60 mL/min/1.73 m2 5.2 Lovastatin Placebo 62 3.90 53.00 304 
JUPITER 2010 No history of CVD, LDL-C < 130 mg/dL eGFR < 60 mL/min/1.73 m2 1.9 Rosuvastatin Placebo 70 2.82 56.00 3267 
LORD 2008 History of CKD, Scr > 120 μmol/L Increased Scr 120 μmol/L 2.5 Atorvastatin Placebo 60 3.22 31.90 123 17 
PANDA 2010 Type 2 DM Urinary albumin creatinine > 5 mg /mmol 2.1 Atorvastatin Atorvastatin 64 3.06 71.70 119 28 
MEGA 2009 No history of CHD and/or stroke eGFR < 60 mL/ min/1.73 m2 5.3 Pravastatin Diet therapy NA 4.00 52.60 2978 
AURORA 2009 ESRD patients, regular haemodialysis for at least 3 months Dialysis 3.2 Rosuvastatin Placebo 64 2.59 NA 2776 40 
CARDS 2009 Type 2 DM or with risk factors such as hypertension, proteinuria, no CVD history eGFR < 60 mL/min/1.73 m2 3.9 Atorvastatin Placebo 65 3.10 53.30 970 
ALLIANCE 2009 With known CHD patients eGFR < 60 mL/min/1.73 m2 4.53 Atordvastatin Usual care (atorvastatin will not be excluded from the usual-care group) 66 3.83 51.30 579 100 
4S 2008 With a history of MI and/or stable angina eGFR < 60 mL/min/1.73 m2 5.5 Simvastatin Placebo 63 4.97 54.80 409 100 
ALLHAT 2008 Stage 1 or 2 hypertension with at least one additional CHD risk factor eGFR < 60 mL/min/1.73 m2 4.8 Pravastatin Usual care 71 3.79 50.80 1557 18 
TNT 2008 With clinically evident CHD eGFR < 60 mL/min/1.73 m2 Atorvastatin 80 mg/day Atodvastatin 10 mg/day 66 2.49 53.00 3107 100 
Melanie S. Joy, 2008 2008 Hyperlipidaemia and CKD patients Dialysis 0.69 Atorvastatin No treatment 65 2.92 NA 45 51 
4D 2005 Type 2 DM receiving maintenance haemodialysis for <2 years Dialysis Atorvastatin Matching placebo 66 3.23 NA 1255 29 
Stegmayr, 2005 2005 GFR < 30 measured by clearance of either creatinine, Cr51-EDTA, or iohexol. eGFR < 30 mL/min/1.73 m2 2.58 Atorvastatin Placebo 68 3.56 NA 143 37 
LIPS 2004 Successfully undergone their first PCI, mild renal impairment Renal impairment, creatinine clearance < 55.9 mL/min 3.8 Fluvastatin Placebo 69 3.39 NA 310 100 
Vincenzo Panichi, 2005 2005 CRF with hypercholesterolaemia (LDL-C > 100 mg/dL) Mean creatinine clearance 45 mL/min 0.5 Simvastatin Placebo 58 3.59 45.00 55 NA 
Dornbrook, 2005 2005 Hyperlipidaemia and undergoing long-term dialysis Dialysis 1.67 Atorvastatin No treatment 66 3.05 NA 19 NA 
Verma, 2005 2005 GFR < 60; no clinical evidence of acute renal failure eGFR < 60 mL/min/1.73 m2 0.38 Rosuvastatin No treatment 73 3.62 42.30 91 
UK-HARP-I 2005 Scr ≥ 150 μmol/L Scr ≥ 150 μmol/L Simvastatin Placebo 54 3.21 NA 448 
PREVEND IT 2004 No antihypertension therapy and Tchol < 8 mmol/L or Tchol < 5 previous MI Microalbuminuria with 15–300 mg/24 h 3.83 Pravastatin Placebo 52 4.10 NA 864 
Verglione, 2004 2004 C-reactive protein ≥ 3 mg/L; undergo HD treatment for at least 6 months Dialysis 0.5 Atorvastatin Placebo 65 NA NA 33 NA 
Tonelli, 2004 (PPP) 2004 CKD subgroup of trials in WOSCOPS, LIPID, CARE eGFR < 60 mL/min/1.73 m2 Pravastatin Placebo NA NA NA 16 824 NA 
Lins, 2004 2004 CRF treated with haemodialysis > 3months and hyperlipidaemia Dialysis 0.23 Atordvastatin Placebo 64 3.39 NA 42 NA 
CARE 2003 GFR < 60, with AMI and hyperlipidaemia eGFR < 60 mL/min/1.73 m2 Pravastatin Placebo 63 3.61 53.20 690 11 
MRC/BHF-HPS 2003 Without CVD in previous 6 months Scr > 110 µmol/L for women, >130 mol/L for men, but < 200 µmol/L for both 4.8 Simvastatin Placebo NA NA NA 1329 NA 
Saltissi, 2002 2002 HD or CAPD patients Dialysis 0.5 Simvastatin + diet Placebo + diet 59 NA NA 57 NA 
PERFECT 1997 Age 18–75 receiving haemodialysis or CAPD, no cardiovascular history Dialysis 0.5 Simvastatin Placebo NA 4.10 NA 107 NA 
Rayner, 1996 1996 IMN patients with an Scr < 150 µmol/L, urine protein ≥ 3.5/24 h, cholesterol > 6.1 mmol/L were eligible the trial IMN patients with Scr < 150 µmol/L, urine protein ≥ 3.5 g/24 h 1.61 Simvastatin Low cholesterol diet or diet alone 42 8.00 84.30 17 12 
Study Year Inclusion criteria Definition of CKD Duration of time, year Treatment group Control group Mean age, years Baseline
 
Number of patients History of CVD (%) 
LDL- C, mmol/L eGFR, mL/min/1.73 m2 
Han, 2011 2011 PD > 3 months Dialysis 0.5 Rosuvastatin 10 mg/day + ARB 80 mg/day Placebo + ARB 80 mg/day 49 4.83 NA 124 
ATTEMP 2011 CKD stage 3 patients with metabolic syndrome, no CVD or DM CKD stage 3, eGFR = 30–59 mL/min/1.73 m2 3.5 Atorvastatin LDL-C target on 100 mg/L Atorvastatin LDL-C target on 130 mg/dL 57 4.37 47.60 349 
SHARP 2011 History of CKD, age > 40, Scr: men >150 µmol/L, women >130 µmol/L Increased Scr: men >150 µmol/L, women >130 µmol/L Simvastatin + ezetimibe Placebo 62 2.70 26.60 9438 15 
Air Force/Texas 2009 Hyperlipidaemia, no CVD or DM eGFR < 60 mL/min/1.73 m2 5.2 Lovastatin Placebo 62 3.90 53.00 304 
JUPITER 2010 No history of CVD, LDL-C < 130 mg/dL eGFR < 60 mL/min/1.73 m2 1.9 Rosuvastatin Placebo 70 2.82 56.00 3267 
LORD 2008 History of CKD, Scr > 120 μmol/L Increased Scr 120 μmol/L 2.5 Atorvastatin Placebo 60 3.22 31.90 123 17 
PANDA 2010 Type 2 DM Urinary albumin creatinine > 5 mg /mmol 2.1 Atorvastatin Atorvastatin 64 3.06 71.70 119 28 
MEGA 2009 No history of CHD and/or stroke eGFR < 60 mL/ min/1.73 m2 5.3 Pravastatin Diet therapy NA 4.00 52.60 2978 
AURORA 2009 ESRD patients, regular haemodialysis for at least 3 months Dialysis 3.2 Rosuvastatin Placebo 64 2.59 NA 2776 40 
CARDS 2009 Type 2 DM or with risk factors such as hypertension, proteinuria, no CVD history eGFR < 60 mL/min/1.73 m2 3.9 Atorvastatin Placebo 65 3.10 53.30 970 
ALLIANCE 2009 With known CHD patients eGFR < 60 mL/min/1.73 m2 4.53 Atordvastatin Usual care (atorvastatin will not be excluded from the usual-care group) 66 3.83 51.30 579 100 
4S 2008 With a history of MI and/or stable angina eGFR < 60 mL/min/1.73 m2 5.5 Simvastatin Placebo 63 4.97 54.80 409 100 
ALLHAT 2008 Stage 1 or 2 hypertension with at least one additional CHD risk factor eGFR < 60 mL/min/1.73 m2 4.8 Pravastatin Usual care 71 3.79 50.80 1557 18 
TNT 2008 With clinically evident CHD eGFR < 60 mL/min/1.73 m2 Atorvastatin 80 mg/day Atodvastatin 10 mg/day 66 2.49 53.00 3107 100 
Melanie S. Joy, 2008 2008 Hyperlipidaemia and CKD patients Dialysis 0.69 Atorvastatin No treatment 65 2.92 NA 45 51 
4D 2005 Type 2 DM receiving maintenance haemodialysis for <2 years Dialysis Atorvastatin Matching placebo 66 3.23 NA 1255 29 
Stegmayr, 2005 2005 GFR < 30 measured by clearance of either creatinine, Cr51-EDTA, or iohexol. eGFR < 30 mL/min/1.73 m2 2.58 Atorvastatin Placebo 68 3.56 NA 143 37 
LIPS 2004 Successfully undergone their first PCI, mild renal impairment Renal impairment, creatinine clearance < 55.9 mL/min 3.8 Fluvastatin Placebo 69 3.39 NA 310 100 
Vincenzo Panichi, 2005 2005 CRF with hypercholesterolaemia (LDL-C > 100 mg/dL) Mean creatinine clearance 45 mL/min 0.5 Simvastatin Placebo 58 3.59 45.00 55 NA 
Dornbrook, 2005 2005 Hyperlipidaemia and undergoing long-term dialysis Dialysis 1.67 Atorvastatin No treatment 66 3.05 NA 19 NA 
Verma, 2005 2005 GFR < 60; no clinical evidence of acute renal failure eGFR < 60 mL/min/1.73 m2 0.38 Rosuvastatin No treatment 73 3.62 42.30 91 
UK-HARP-I 2005 Scr ≥ 150 μmol/L Scr ≥ 150 μmol/L Simvastatin Placebo 54 3.21 NA 448 
PREVEND IT 2004 No antihypertension therapy and Tchol < 8 mmol/L or Tchol < 5 previous MI Microalbuminuria with 15–300 mg/24 h 3.83 Pravastatin Placebo 52 4.10 NA 864 
Verglione, 2004 2004 C-reactive protein ≥ 3 mg/L; undergo HD treatment for at least 6 months Dialysis 0.5 Atorvastatin Placebo 65 NA NA 33 NA 
Tonelli, 2004 (PPP) 2004 CKD subgroup of trials in WOSCOPS, LIPID, CARE eGFR < 60 mL/min/1.73 m2 Pravastatin Placebo NA NA NA 16 824 NA 
Lins, 2004 2004 CRF treated with haemodialysis > 3months and hyperlipidaemia Dialysis 0.23 Atordvastatin Placebo 64 3.39 NA 42 NA 
CARE 2003 GFR < 60, with AMI and hyperlipidaemia eGFR < 60 mL/min/1.73 m2 Pravastatin Placebo 63 3.61 53.20 690 11 
MRC/BHF-HPS 2003 Without CVD in previous 6 months Scr > 110 µmol/L for women, >130 mol/L for men, but < 200 µmol/L for both 4.8 Simvastatin Placebo NA NA NA 1329 NA 
Saltissi, 2002 2002 HD or CAPD patients Dialysis 0.5 Simvastatin + diet Placebo + diet 59 NA NA 57 NA 
PERFECT 1997 Age 18–75 receiving haemodialysis or CAPD, no cardiovascular history Dialysis 0.5 Simvastatin Placebo NA 4.10 NA 107 NA 
Rayner, 1996 1996 IMN patients with an Scr < 150 µmol/L, urine protein ≥ 3.5/24 h, cholesterol > 6.1 mmol/L were eligible the trial IMN patients with Scr < 150 µmol/L, urine protein ≥ 3.5 g/24 h 1.61 Simvastatin Low cholesterol diet or diet alone 42 8.00 84.30 17 12 

CKD, chronic kidney disease; CVD, cardiovascular event; MI, myocardial infarction; AMI, acute myocardial infarction; CHD, coronary heart disease; CRF, chronic renal failure; DM, diabetes mellitus; PD, peritoneal dialysis; HD, haematodialysis dialysis; CAPD, continuous ambulatory peritoneal dialysis; IMN, idiopathic membranous nephropathy; Scr, serum creatinine; ESRD, end stage renal disease.

Figure 2

Summary of the effects of statin therapy on major cardiovascular events stratified by kidney function. Only one trial and one subgroup (SHARP >60 and Rayner, 1996) were in chronic kidney disease (CKD) 2 stage with few endpoints (4 cardiovascular events and 105 patients), and we combined chronic kidney disease stage 3 and chronic kidney disease stage 2 into one subgroup.

Figure 2

Summary of the effects of statin therapy on major cardiovascular events stratified by kidney function. Only one trial and one subgroup (SHARP >60 and Rayner, 1996) were in chronic kidney disease (CKD) 2 stage with few endpoints (4 cardiovascular events and 105 patients), and we combined chronic kidney disease stage 3 and chronic kidney disease stage 2 into one subgroup.

The mean age of the study participants ranged between 42 and 73 years. Included studies were undertaken in Europe, North America, and in some part of Asia and Africa. The agents used in the studies varied: 12 studies assessed the effects of atorvastatin, 8 assessed simvastatin, 5 assessed pravastatin, 4 assessed rosuvastatin, where 1 assessed fluvastatin and 1 lovastatin.

We also recorded key indicators of trial quality, in particular the process of randomization, concealment of allocation, and the use of intention-to-treat analysis techniques, blinding, withdraws and dropouts (see Supplementary material online, Table S1). Overall, 13 trials had a Jadad scale of 4, others scored ≤3.

Data regarding the effects of statin on major cardiovascular events were available from 22 trials, including 44 096 participants and 6695 events. Overall, statin therapy produced a 23% reduction in the risk of cardiovascular events (RR 0.77, 95% CI 0.70–0.85, P<0.001) (Figure 2A) or an 18% per 1 mmol/L LDL (RR 0.82, 95% CI 0.74–0.91, P<0.001, see Supplementary material online, Figure S2) with evidence of heterogeneity in the results of individual trials. Subgroup analysis showed that statin effect was significantly modified by kidney function (Figure 2B). Four trials with 4154 participants that compared more vs. less intensive statin regimens showed that intensive statin therapy reduced cardiovascular events by 28% in people with CKD (see Supplementary material online, Figure S3).

Data for coronary events were available from 15 trials8–10,19–29 including 26 262 patients in whom 2516 events were recorded. Statin therapy reduced the risk of coronary events by 22% (RR 0.78, 95% CI 0.69–0.88) without evidence of heterogeneity (I2 = 29.6%, P = 0.134) (Figure 3). Eight trials reported stroke, including 21 505 and 647 events. Overall, there was no effect of statin therapy on the risk of stroke (RR 0.79, 95% CI 0.56–1.12) with evidence of heterogeneity between trials (P-value for heterogeneity = 0.001).

Figure 3

Summary of the relative risks of all outcomes. aKidney failure events defined as a 25% decrease in the estimated GFR, doubling of serum creatinine, or ESRD.

Figure 3

Summary of the relative risks of all outcomes. aKidney failure events defined as a 25% decrease in the estimated GFR, doubling of serum creatinine, or ESRD.

Cardiovascular death was reported in 11 trials including 31 859 patients among whom 2123 events were observed. Nineteen trials reported all-cause death, including 39 722 patients and 6653 events. Statin therapy reduced all-cause death (RR 0.92, 95% CI 0.85–0.99) and also cardiovascular death (RR 0.91, 95% CI 0.84–0.99) without clear evidence of heterogeneity (Figure 3).

Kidney failure events defined as a 25% decrease in the estimated GFR, doubling of serum creatinine, or ESRD were reported in six trials8,20,23,26,30,31 including 11 924 participants and 2824 events. There was no clear evidence that statins reduced the risk of kidney failure (RR 0.95, 95% CI 0.90–1.01) (Figure 3).

The heterogeneity in the effect across the included studies was assessed by subgroup analysis and meta-regression. This revealed that the effect of statin therapy on major cardiovascular events was modified by the average baseline kidney function of the participants in the included trials (P-value for heterogeneity < 0.001), with a progressively smaller relative risk reduction (RRR) with a lower estimated GFR. The RRR for cardiovascular event in trials with CKD stage 5 including patients with dialysis (8 trials8–10,27,29,32 with 7987 participants) was 8% (95% CI 1–14, I2 = 0%) and 22% (95% CI 4–37, I2 = 0%) in stage 4 (2 trials or subgroups,8,27 2598 patients) and 31% (95% CI 4–37, I2 = 0%) in stage 3 or 2 (11 trials or subgroups with 12 330 participants). Only two small trials or subgroups included 107 participants with CKD stage 2, so meta-analysis was not separately done in this group. The benefits of statin in patients not on dialysis (RR 0.70, 95% CI 0.63–0.88) was larger (P-value for heterogeneity < 0.001) than those in patients on dialysis (RR 0.92, 95% CI 0.85–0.99). Adjusting the risk ratio for cardiovascular events by weighted average LDL-C reduction did not substantially modify these findings. Reductions in the risk of cardiovascular events per 1 mmol/L LDL-C reduction at the end of each trial were 27% (RR 0.73, 95% CI 0.65–0.83, P < 0.001) in patients with CKD not requiring dialysis compared with 10% (RR 0.90, 95% CI 0.83–0.97, P = 0.01) in patients requiring dialysis (P-value for heterogeneity = 0.007) (see Supplementary material online, Figure S2). Similar findings were observed for coronary events (RR 0.69, 95% CI 0.58–0.83 in the non-dialysis population and RR 0.91, 95% CI 0.81–1.02 in the dialysis population, P-value for heterogeneity = 0.042) and stroke (RR 0.61, 95% CI 0.39–0.95 in non-dialysis patients and RR 1.16, 95% CI 0.91–1.47 in dialysis patients, P-value for heterogeneity = 0.001) (Figure 3).

As the risk of CVD increased as the kidney function deteriorated, but with the risk ratio lower, we calculated the absolute risk reduction among patients with different CKD stages [Table 2; we also provide three models for the number needed to treat (NNT), see Supplementary material online, Tables S3.1–3.3]. The NNT to reduce one major cardiovascular event was 46 in CKD stage 5 (25–257), 36 in CKD stage 4 (19–330), and 24 in CKD stages 2–3 (19–32).

Table 2

Absolute risk reduction and number needed to treat of statin in patients with chronic kidney disease

CKD stagea Statin, number of patients Placebo, number of patients Experiment CVE Control CVE ARR (95% CI) (per study duration on average) NNT (95% CI) (per study duration on average) 
CKD stage 5 4283 4237 933 1015 0.022 (0.004–0.040) 46 (25–257) 
CKD stage 4 1263 1335 134 179 0.028 (0.003–0.053) 36 (19–330) 
CKD stages 3, 2 6194 6211 504 764 0.042 (0.031–0.052) 24 (19–32) 
CKD stagea Statin, number of patients Placebo, number of patients Experiment CVE Control CVE ARR (95% CI) (per study duration on average) NNT (95% CI) (per study duration on average) 
CKD stage 5 4283 4237 933 1015 0.022 (0.004–0.040) 46 (25–257) 
CKD stage 4 1263 1335 134 179 0.028 (0.003–0.053) 36 (19–330) 
CKD stages 3, 2 6194 6211 504 764 0.042 (0.031–0.052) 24 (19–32) 

CVE, cardiovascular event.

aCKD stage 5: estimated GFR (eGFR) <15 mL/min/1.73 m2; CKD stage 4: eGFR 15–30 mL/min/1.73 m2; CKD stage 3: eGFR 30–60 mL/min/1.73 m2; CKD stage 2: eGFR 60–90 mL/min/1.73 m2.

Subgroup analysis was done for major cardiovascular events according to other baseline characteristics (Figure 4). The effect sizes were greater in trials that recorded a higher mean baseline LDL-C concentration (P-value for heterogeneity = 0.012). On univariate meta-regression, there was a trend for statin therapy to produce the greatest benefit when LDL-C concentrations were improved most (Figure 5, P = 0.062) in non-dialysis patients. In contrast, no clear relationship between LDL-C reduction and cardiovascular benefit was observed in patients receiving dialysis.

Figure 4

Subgroup analyses for the effects of statin on major cardiovascular events. aTrials that recruited only patients with chronic kidney disease. bTrials that were conducted in the general population where subgroups of patients with kidney disease were available.

Figure 4

Subgroup analyses for the effects of statin on major cardiovascular events. aTrials that recruited only patients with chronic kidney disease. bTrials that were conducted in the general population where subgroups of patients with kidney disease were available.

Figure 5

Univariate meta-regression exploring the role of achieved lipid concentrations on the effectiveness of statin therapy on cardiovascular events. Meta-regression of cardiovascular events and LDL cholesterol reduction difference between statin and placebo or conventional therapy groups. Black circle were trials exclusively in dialysis patients (PREVEND IT, ATTEMP, Air Force, JUPITER, PANDER, ALLIANCE, LIPS, Rayner 1996). White circle were trials exclusively in non-dialysis patients(AURORA; 4D; Melanie S. Joy, 2008; Saltissi, 2002). Grey Circles were trials of mixed population, respectively indicated Stegmayr 2005 and SHARP. They were included in both non-dialysis and dialysis trials in the regression analysis. P-value for non-dialysis patients = 0.062, coefficient = −0.503; P-value for dialysis patients = 0.625, coefficient = −0.234.

Figure 5

Univariate meta-regression exploring the role of achieved lipid concentrations on the effectiveness of statin therapy on cardiovascular events. Meta-regression of cardiovascular events and LDL cholesterol reduction difference between statin and placebo or conventional therapy groups. Black circle were trials exclusively in dialysis patients (PREVEND IT, ATTEMP, Air Force, JUPITER, PANDER, ALLIANCE, LIPS, Rayner 1996). White circle were trials exclusively in non-dialysis patients(AURORA; 4D; Melanie S. Joy, 2008; Saltissi, 2002). Grey Circles were trials of mixed population, respectively indicated Stegmayr 2005 and SHARP. They were included in both non-dialysis and dialysis trials in the regression analysis. P-value for non-dialysis patients = 0.062, coefficient = −0.503; P-value for dialysis patients = 0.625, coefficient = −0.234.

Key adverse outcomes were reported by few trials. For hepatic impairment6,8,9,25,26,32,33 (RR 1.13, 95% CI 0.92–1.39), muscle pain6,26–28,34–36 (RR 1.02, 95% CI 0.95–1.09), increased creatinine kinase level6,8,16,22,24,26,28,30,31,37,38 (RR 1.18, 95% CI 0.89–1.55), cancer morbidity6,8,24,39 (RR 0.95, 95% CI 0.87–1.05), and severe adverse event8,9,25,26,30,32,36 (RR 0.95, 95% CI 0.89–1.03) in the analysis (Figure 6), no significant difference in risk was observed in the statin-treated participants.

Figure 6

Adverse events of statin reported in the trials with chronic kidney disease. Drug-related adverse events (hepatic disorder defined as ALT or AST > normal × 3 times; muscle pain; creatinine kinase > normal × 3 times; cancer new onset; severe adverse event) were involved in the meta-analysis.

Figure 6

Adverse events of statin reported in the trials with chronic kidney disease. Drug-related adverse events (hepatic disorder defined as ALT or AST > normal × 3 times; muscle pain; creatinine kinase > normal × 3 times; cancer new onset; severe adverse event) were involved in the meta-analysis.

The conclusions were not changed after adjustment for publication bias with the trim-and-fill method (data not shown).

Discussion

The management of lipids in people with CKD has been an area of intense debate over recent years, particularly in those with more advanced kidney dysfunction. This large quantitative review, including 31 trials with more than 48 000 individuals, suggests that therapy with statin reduces the risk of cardiovascular events across different levels of kidney function. Major cardiovascular events are reduced by 23%, including a 22% reduction in coronary events, and 9% reduction in cardiovascular or all-cause death. No significant effect was observed on the risk of kidney failure, or on the risk of adverse events including cancer mortality.

The most important new finding of this study is the clear result that the effect of statin therapy is significantly modified by kidney function. The observed beneficial effects appear to be smaller in people with stage 5 kidney disease and those requiring dialysis. Similar findings were observed for coronary heart disease and stroke. Importantly, the absolute risk reductions and NNT were only slightly less in people with advanced kidney disease, suggesting that statin therapy still confers important benefits in these individuals. In this analysis, we did not find that the adverse events of statin were increased in the patients with CKD, which suggested the safety of using statin in this population. However, this is still needed to be cautious given many trials included in this meta-analysis are post hoc analysis, and adverse events are reported by only a few trials. For the effect on stroke risk in patients with dialysis, the risk ratio even goes in the opposite direction (RR 1.16, 95% CI 0.90–1.47), and more data are still needed to evaluate the safety of statin in dialysis patients.

The effects of LDL-lowering with statin therapy in patients without CKD have been described by the Cholesterol Treatment Trialists' (CTT) Collaboration, and shown that statin therapy can safely reduce the 5-year incidence of major coronary events, coronary revascularization, and stroke by about one-fifth per mmol/L reduction in LDL-C.40 In this study, LDL-C-lowering with statin in CKD could yield 18% reduction per 1.0 mmol/L reduction in major cardiovascular events, which is close consistent with the effects seen in the CTT study. Our study is also consistent with the results from the SHARP study and supports statin use in patients with CKD, including dialysis patients. However, SHARP did not have sufficient power to assess the effects separately in dialysis and non-dialysis patients. This large meta-analysis with more than four times of participants strongly supports larger benefits in patients with less severe renal impairment. Further support comes from the meta-regression analysis that a linear association trend exists in patients with non-dialysis although not obvious in patients with dialysis.

The reason for the lesser RRR in patients with ESRD than those achieved in patients with less severe kidney disease may reflect differences in the distribution of CVD among these groups of patients. Cardiovascular disease may have different aetiological pathways in people with ESRD compared with those with better renal function, and indeed may have a different pathophysiology.39,41,42 Cardiovascular risk factors specific to ESRD include calcium and phosphorus dysregulation, anaemia, hyperhomocysteinaemia, increased levels of oxidant stress, and chronic inflammation.33,37–39,43–45 In addition, the burden of cardiovascular dysfunction may be further accelerated by haemodynamic instability in dialysis patients. It is postulated that statins may not impact the substantial proportion of cardiovascular events in ESRD populations resulting from non-ischaemic myocardial abnormalities, left ventricular hypertrophy, and fluctuations in electrolytes and fluid volumes.43 These may explain the more modest relative effect of statins than that seen in an earlier stage of kidney disease.

Trials including individuals with high average baseline LDL-C concentrations reported significantly greater proportional risk reductions, a finding that accords with the results in the general population. Importantly, we noted a significant relationship between the magnitude of LDL-C-lowering achieved with therapy and the reported risk reductions in patients with non-dialysis patients, although this phenomenon was not observed in patients with ESRD. This further supports the hypothesis that the excess of cardiovascular events observed in people with advanced kidney disease may not be atherosclerotic in nature, and therefore not able to be reduced with statins.7 However, in this analysis, given that the rates of cardiovascular events and mortality consistently increase as kidney function deteriorates, clinically meaningful absolute risk reductions can still be achieved in patients with severe kidney dysfunction. In the subgroup analysis, we also noted significant heterogeneity between trials only involving patients with kidney disease and trials in the general population where the subgroup with CKD was available. This difference may be due to different kidney functions among these trials. The trials with CKD are mostly studies involving patients with dialysis, whereas in the post hoc analysis, participants were mainly non-dialysis patients.

This meta-analysis benefits from a large volume of data available, and the resultant precision in the observed benefits across a broad range of kidney function. Our study does, however, have limitations mainly as a result of it being based on published data, which limits the capacity to fully explore effects in subgroups. The different definitions used by the contributing trials cannot be fully integrated, and the outcome definitions, in particular, required some grouping of event types. Also in the meta-regression assessing kidney function and the effect of statins, we were only able to use the mean baseline GFR of the included trials rather than individual patient kidney function.

In conclusion, this study has provided strong evidence that statin therapy reduces the risk of major vascular events, as well as cardiovascular and all-cause death in patients with CKD, across a broad range of kidney functions including patients with dialysis. Although the relative vascular protection of statins is significantly modified by kidney function, meaningful reductions in absolute risk would be expected to be achieved in every stage of CKD. Additional protective strategies are required to address the large excess of cardiovascular events in the population with ESRD.

Supplementary material

Supplementary material is available at European Heart Journal online.

Funding

This study was supported by grants from the Major State Basic Research Development Program of China (973 program, No. 2012CB517700), National Natural Science Foundation of China (No. 81270795, 30825021), Natural Science Fund of China to the Innovation Research Group (81021004) and Program for New Century Excellent Talents in University from the Ministry of Education of China (NCET-12-0011).

Conflict of interest: none declared.

References

1
James
MT
Hemmelgarn
BR
Tonelli
M
Early recognition and prevention of chronic kidney disease
Lancet
 , 
2010
, vol. 
375
 (pg. 
1296
-
1309
)
2
Go
AS
Chertow
GM
Fan
D
McCulloch
CE
Hsu
CY
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization
N Engl J Med
 , 
2004
, vol. 
351
 (pg. 
1296
-
1305
)
3
Yach
D
Leeder
SR
Bell
J
Kistnasamy
B
Global chronic diseases
Science
 , 
2005
, vol. 
307
 pg. 
317
 
4
Sarnak
MJ
Levey
AS
Cardiovascular disease and chronic renal disease: a new paradigm
Am J Kidney Dis
 , 
2000
, vol. 
35
 
4 Suppl. 1
(pg. 
S117
-
S131
)
5
Snyder
JJ
Collins
AJ
KDOQI hypertension, dyslipidemia, and diabetes care guidelines and current care patterns in the United States CKD population: National Health and Nutrition Examination Survey 1999–2004
Am J Nephrol
 , 
2009
, vol. 
30
 (pg. 
44
-
54
)
6
Liu
Y
Coresh
J
Eustace
JA
Longenecker
JC
Jaar
B
Fink
NE
Tracy
RP
Powe
NR
Klag
MJ
Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition
JAMA
 , 
2004
, vol. 
291
 (pg. 
451
-
459
)
7
Foley
RN
Parfrey
PS
Sarnak
MJ
Clinical epidemiology of cardiovascular disease in chronic renal disease
Am J Kidney Dis
 , 
1998
, vol. 
32
 
5 Suppl. 3
(pg. 
S112
-
S119
)
8
Baigent
C
Landray
MJ
Reith
C
Emberson
J
Wheeler
DC
Tomson
C
Wanner
C
Krane
V
Cass
A
Craig
J
Neal
B
Jiang
L
Hooi
LS
Levin
A
Agodoa
L
Gaziano
M
Kasiske
B
Walker
R
Massy
ZA
Feldt-Rasmussen
B
Krairittichai
U
Ophascharoensuk
V
Fellstrom
B
Holdaas
H
Tesar
V
Wiecek
A
Grobbee
D
de Zeeuw
D
Gronhagen-Riska
C
Dasgupta
T
Lewis
D
Herrington
W
Mafham
M
Majoni
W
Wallendszus
K
Grimm
R
Pedersen
T
Tobert
J
Armitage
J
Baxter
A
Bray
C
Chen
Y
Chen
Z
Hill
M
Knott
C
Parish
S
Simpson
D
Sleight
P
Young
A
Collins
R
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial
Lancet
 , 
2011
, vol. 
377
 (pg. 
2181
-
2192
)
9
Fellstrom
BC
Jardine
AG
Schmieder
RE
Holdaas
H
Bannister
K
Beutler
J
Chae
DW
Chevaile
A
Cobbe
SM
Gronhagen-Riska
C
De Lima
JJ
Lins
R
Mayer
G
McMahon
AW
Parving
HH
Remuzzi
G
Samuelsson
O
Sonkodi
S
Sci
D
Suleymanlar
G
Tsakiris
D
Tesar
V
Todorov
V
Wiecek
A
Wuthrich
RP
Gottlow
M
Johnsson
E
Zannad
F
Rosuvastatin and cardiovascular events in patients undergoing hemodialysis
N Engl J Med
 , 
2009
, vol. 
360
 (pg. 
1395
-
1407
)
10
Wanner
C
Krane
V
Marz
W
Olschewski
M
Mann
JF
Ruf
G
Ritz
E
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis
N Engl J Med
 , 
2005
, vol. 
353
 (pg. 
238
-
248
)
11
Palmer
SC
Craig
JC
Navaneethan
SD
Tonelli
M
Pellegrini
F
Strippoli
GF
Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis
Ann Intern Med
 , 
2012
, vol. 
157
 (pg. 
263
-
275
)
12
Upadhyay
A
Earley
A
Lamont
JL
Haynes
S
Wanner
C
Balk
EM
Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis
Ann Intern Med
 , 
2012
, vol. 
157
 (pg. 
251
-
262
)
13
Jadad
AR
Moore
RA
Carroll
D
Jenkinson
C
Reynolds
DJ
Gavaghan
DJ
McQuay
HJ
Assessing the quality of reports of randomized clinical trials: is blinding necessary?
Control Clin Trials
 , 
1996
, vol. 
17
 (pg. 
1
-
12
)
14
Woodward
M
Epidemiology: Study design and data analysis
 , 
2005
2nd edition
 
Boca Raton, FL, USA: Chapman and Hall/CRC
15
Law
MR
Morris
JK
Wald
NJ
Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies
BMJ
 , 
2009
, vol. 
338
 pg. 
b1665
 
16
Han
SH
Kang
EW
Yoon
SJ
Yoon
HS
Lee
HC
Yoo
TH
Choi
KH
Han
DS
Kang
SW
Combined vascular effects of HMG-CoA reductase inhibitor and angiotensin receptor blocker in non-diabetic patients undergoing peritoneal dialysis
Nephrol Dial Transplant
 , 
2011
, vol. 
26
 (pg. 
3722
-
3728
)
17
Joy
MS
Dornbrook-Lavender
KA
Chin
H
Hogan
SL
Denu-Ciocca
C
Effects of atorvastatin on Lp(a) and lipoprotein profiles in hemodialysis patients
Ann Pharmacother
 , 
2008
, vol. 
42
 (pg. 
9
-
15
)
18
Dornbrook-Lavender
KA
Joy
MS
Denu-Ciocca
CJ
Chin
H
Hogan
SL
Pieper
JA
Effects of atorvastatin on low-density lipoprotein cholesterol phenotype and C-reactive protein levels in patients undergoing long-term dialysis
Pharmacotherapy
 , 
2005
, vol. 
25
 (pg. 
335
-
344
)
19
Asselbergs
FW
Diercks
GF
Hillege
HL
van Boven
AJ
Janssen
WM
Voors
AA
de Zeeuw
D
de Jong
PE
van Veldhuisen
DJ
van Gilst
WH
Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria
Circulation
 , 
2004
, vol. 
110
 (pg. 
2809
-
2816
)
20
Chonchol
M
Cook
T
Kjekshus
J
Pedersen
TR
Lindenfeld
J
Simvastatin for secondary prevention of all-cause mortality and major coronary events in patients with mild chronic renal insufficiency
Am J Kidney Dis
 , 
2007
, vol. 
49
 (pg. 
373
-
382
)
21
Colhoun
HM
Betteridge
DJ
Durrington
PN
Hitman
GA
Neil
HA
Livingstone
SJ
Charlton-Menys
V
DeMicco
DA
Fuller
JH
Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS)
Am J Kidney Dis
 , 
2009
, vol. 
54
 (pg. 
810
-
819
)
22
Collins
R
Armitage
J
Parish
S
Sleigh
P
Peto
R
MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial
Lancet
 , 
2003
, vol. 
361
 (pg. 
2005
-
2016
)
23
Kendrick
J
Shlipak
MG
Targher
G
Cook
T
Lindenfeld
J
Chonchol
M
Effect of lovastatin on primary prevention of cardiovascular events in mild CKD and kidney function loss: a post hoc analysis of the Air Force/Texas Coronary Atherosclerosis Prevention Study
Am J Kidney Dis
 , 
2010
, vol. 
55
 (pg. 
42
-
49
)
24
Lemos
PA
Serruys
PW
de Feyter
P
Mercado
NF
Goedhart
D
Saia
F
Arampatzis
CA
Soares
PR
Ciccone
M
Arquati
M
Cortellaro
M
Rutsch
W
Legrand
V
Long-term fluvastatin reduces the hazardous effect of renal impairment on four-year atherosclerotic outcomes (a LIPS substudy)
Am J Cardiol
 , 
2005
, vol. 
95
 (pg. 
445
-
451
)
25
Nakamura
H
Mizuno
K
Ohashi
Y
Yoshida
T
Hirao
K
Uchida
Y
Pravastatin and cardiovascular risk in moderate chronic kidney disease
Atherosclerosis
 , 
2009
, vol. 
206
 (pg. 
512
-
517
)
26
Ridker
PM
MacFadyen
J
Cressman
M
Glynn
RJ
Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial
J Am Coll Cardiol
 , 
2010
, vol. 
55
 (pg. 
1266
-
1273
)
27
Stegmayr
BG
Brannstrom
M
Bucht
S
Crougneau
V
Dimeny
E
Ekspong
A
Eriksson
M
Granroth
B
Grontoft
KC
Hadimeri
H
Holmberg
B
Ingman
B
Isaksson
B
Johansson
G
Lindberger
K
Lundberg
L
Mikaelsson
L
Olausson
E
Persson
B
Stenlund
H
Wikdahl
AM
Low-dose atorvastatin in severe chronic kidney disease patients: a randomized, controlled endpoint study
Scand J Urol Nephrol
 , 
2005
, vol. 
39
 (pg. 
489
-
497
)
28
Tonelli
M
Moye
L
Sacks
FM
Cole
T
Curhan
GC
Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease
J Am Soc Nephrol
 , 
2003
, vol. 
14
 (pg. 
1605
-
1613
)
29
Vernaglione
L
Cristofano
C
Muscogiuri
P
Chimienti
S
Does atorvastatin influence serum C-reactive protein levels in patients on long-term hemodialysis?
Am J Kidney Dis
 , 
2004
, vol. 
43
 (pg. 
471
-
478
)
30
Fassett
RG
Robertson
IK
Ball
MJ
Geraghty
DP
Coombes
JS
Effect of atorvastatin on kidney function in chronic kidney disease: a randomised double-blind placebo-controlled trial
Atherosclerosis
 , 
2010
, vol. 
213
 (pg. 
218
-
224
)
31
Rayner
BL
Byrne
MJ
van Zyl Smit
R
A prospective clinical trial comparing the treatment of idiopathic membranous nephropathy and nephrotic syndrome with simvastatin and diet, versus diet alone
Clin Nephrol
 , 
1996
, vol. 
46
 (pg. 
219
-
224
)
32
Saltissi
D
Morgan
C
Rigby
RJ
Westhuyzen
J
Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis
Am J Kidney Dis
 , 
2002
, vol. 
39
 (pg. 
283
-
290
)
33
Luciak
M
Trznadel
K
Free oxygen species metabolism during haemodialysis with different membranes
Nephrol Dial Transplant
 , 
1991
, vol. 
6
 
Suppl. 3
(pg. 
66
-
70
)
34
Verma
A
Ranganna
KM
Reddy
RS
Verma
M
Gordon
NF
Effect of rosuvastatin on C-reactive protein and renal function in patients with chronic kidney disease
Am J Cardiol
 , 
2005
, vol. 
96
 (pg. 
1290
-
1292
)
35
Baigent
C
Landray
M
Leaper
C
Altmann
P
Armitage
J
Baxter
A
Cairns
HS
Collins
R
Foley
RN
Frighi
V
Kourellias
K
Ratcliffe
PJ
Rogerson
M
Scoble
JE
Tomson
CR
Warwick
G
Wheeler
DC
First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease
Am J Kidney Dis
 , 
2005
, vol. 
45
 (pg. 
473
-
484
)
36
Lins
RL
Matthys
KE
Billiouw
JM
Dratwa
M
Dupont
P
Lameire
NH
Peeters
PC
Stolear
JC
Tielemans
C
Maes
B
Verpooten
GA
Ducobu
J
Carpentier
YA
Lipid and apoprotein changes during atorvastatin up-titration in hemodialysis patients with hypercholesterolemia: a placebo-controlled study
Clin Nephrol
 , 
2004
, vol. 
62
 (pg. 
287
-
294
)
37
Astor
BC
Muntner
P
Levin
A
Eustace
JA
Coresh
J
Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988–1994)
Arch Intern Med
 , 
2002
, vol. 
162
 (pg. 
1401
-
1408
)
38
London
GM
Guerin
AP
Marchais
SJ
Metivier
F
Pannier
B
Adda
H
Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality
Nephrol Dial Transplant
 , 
2003
, vol. 
18
 (pg. 
1731
-
1740
)
39
Francis
ME
Eggers
PW
Hostetter
TH
Briggs
JP
Association between serum homocysteine and markers of impaired kidney function in adults in the United States
Kidney Int
 , 
2004
, vol. 
66
 (pg. 
303
-
312
)
40
Baigent
C
Keech
A
Kearney
PM
Blackwell
L
Buck
G
Pollicino
C
Kirby
A
Sourjina
T
Peto
R
Collins
R
Simes
R
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins
Lancet
 , 
2005
, vol. 
366
 (pg. 
1267
-
1278
)
41
Lindner
A
Charra
B
Sherrard
DJ
Scribner
BH
Accelerated atherosclerosis in prolonged maintenance hemodialysis
N Engl J Med
 , 
1974
, vol. 
290
 (pg. 
697
-
701
)
42
Ribeiro
S
Ramos
A
Brandao
A
Rebelo
JR
Guerra
A
Resina
C
Vila-Lobos
A
Carvalho
F
Remedio
F
Ribeiro
F
Cardiac valve calcification in haemodialysis patients: role of calcium-phosphate metabolism
Nephrol Dial Transplant
 , 
1998
, vol. 
13
 (pg. 
2037
-
2040
)
43
Herzog
CA
Mangrum
JM
Passman
R
Sudden cardiac death and dialysis patients
Semin Dial
 , 
2008
, vol. 
21
 (pg. 
300
-
307
)
44
Roselaar
SE
Nazhat
NB
Winyard
PG
Jones
P
Cunningham
J
Blake
DR
Detection of oxidants in uremic plasma by electron spin resonance spectroscopy
Kidney Int
 , 
1995
, vol. 
48
 (pg. 
199
-
206
)
45
Stenvinkel
P
Heimburger
O
Paultre
F
Diczfalusy
U
Wang
T
Berglund
L
Jogestrand
T
Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure
Kidney Int
 , 
1999
, vol. 
55
 (pg. 
1899
-
1911
)

Supplementary data

Comments

0 Comments